On September 12, 2023, Precision BioSciences held a virtual R&D Day to showcase its groundbreaking ARCUS genome editing platform and the latest advancements in its in vivo gene editing initiatives. This event served as a platform to unveil new preclinical data for both Precision BioSciences’ proprietary programs and its collaborative efforts.
With a renewed focus on its in vivo gene editing portfolio, Precision BioSciences demonstrated its commitment to pushing the boundaries of medical innovation. In line with this dedication, the company introduced PBGENE-PMM, an exciting addition to its expanding portfolio. This potentially curative treatment offers hope for individuals suffering from primary mitochondrial myopathy.
Precision BioSciences is revolutionizing the field of medicine through the utilization of its novel ARCUS genome editing technology. By harnessing the power of ARCUS, the company aims to develop a new class of medicines that can effectively address and potentially cure challenging conditions such as cancer and genetic diseases.
The ARCUS genome editing technology, which was discovered and developed by the talented scientists at Precision BioSciences, is characterized by its precision and versatility. By utilizing sequence-specific DNA-cutting enzymes, known as nucleases, ARCUS enables the insertion (knock in), removal (knock out), or repair of DNA in living cells and tissues.
In addition to its in-house efforts, Precision BioSciences has joined forces with Novartis to collaborate on the development of a potentially curative treatment for various disorders, including sickle cell disease. This partnership exemplifies Precision BioSciences’ commitment to driving transformative change in the field of gene editing.
Precision BioSciences, Inc.
Updated on: 07/12/2023
Debt to equity ratio: Strong Buy
Price to earnings ratio: Sell
Price to book ratio: Strong Buy
DCF: Strong Buy
ROE: Strong Sell
8:00 PM (UTC)
Date:07 December, 2023
|Analyst / firm||Rating|
DTIL (Precision BioSciences Inc.): A Small Biotech Company with Fluctuating Earnings and Revenue Growth
DTIL (Precision BioSciences Inc.) is a biotechnology company that specializes in gene editing and gene therapy. On September 12, 2023, the stock opened at $0.41, slightly lower than the previous day’s closing price of $0.42. Throughout the day, the stock traded within a range of $0.41 to $0.45. The total volume of shares traded was 579,886, which is lower than the average volume of 967,716 over the past three months.
Precision BioSciences has a market capitalization of $48.3 million, indicating that it is a relatively small company in the biotechnology sector. The company has experienced significant fluctuations in its earnings growth. Last year, the earnings growth was -143.59%, reflecting a decline in profitability. However, this year, the company has shown some improvement with earnings growth of +25.59%.
In terms of revenue growth, Precision BioSciences experienced a decline of -78.28% last year. The company’s price-to-sales ratio is 4.17, indicating that investors are willing to pay a premium for each dollar of the company’s sales. The price-to-book ratio is 0.77, suggesting that the stock is trading at a discount to its book value.
Looking at the performance of other biotechnology stocks on September 12, 2023, Leap Therapeutics Inc. (LPTX) saw an increase of $0.08 or 4.32%, Aslan Pharmaceuticals (ASLN) increased by $0.02 or 0.96%, and Portage Biotech Inc (PRTG) increased by $0.04 or 1.51%. Quince Therapeutics (QNCX) did not see any change in its stock price.
Precision BioSciences does not have any upcoming earnings reports until November 14, 2023. However, analysts are forecasting an earnings per share (EPS) of -$0.24 for the current quarter. Precision BioSciences reported annual revenue of $25.1 million last year, along with an annual loss of -$111.6 million. The net profit margin for the company is -444.80%, indicating that it is currently operating at a loss.
Precision BioSciences is part of the health technology sector, specifically the biotechnology industry. The company is headquartered in Durham, North Carolina.
Promising Performances of DTIL Stock: Positive Price Forecasts and Consensus to Buy Precision BioSciences Inc
DTIL stock, the ticker symbol for Precision BioSciences Inc, showed promising performances on September 12, 2023, based on the information provided by CNN Money. The stock has attracted the attention of analysts, who have offered 12-month price forecasts for the company.
According to the data, there are five analysts providing price forecasts for Precision BioSciences Inc. The median target price is $2.50, with a high estimate of $4.00 and a low estimate of $1.40. This indicates a potential increase of 476.57% from the last recorded price of $0.43.
Furthermore, the current consensus among the five polled investment analysts is to buy stock in Precision BioSciences Inc. This rating has remained steady since September, indicating a continued positive sentiment towards the company.
In terms of financial performance, Precision BioSciences Inc reported earnings per share of -$0.24 for the current quarter. This suggests a loss for the company during this period. However, the company reported sales of $7.0 million, indicating a positive revenue stream.
Investors and analysts are eagerly awaiting the reporting date for Precision BioSciences Inc’s financial results, which is scheduled for November 14. This will provide further insights into the company’s performance and financial health.
Overall, the data suggests that DTIL stock has shown promising performances on September 12, 2023. The positive price forecasts from analysts, along with the consensus to buy the stock, indicate a favorable outlook for Precision BioSciences Inc. However, investors should closely monitor the upcoming financial results to make informed decisions about their investments.